Rabi Hanna, MD, is the director of the Pediatric Bone Marrow Transplantation at Cleveland Clinic Children’s Hospital, Department of Pediatric Hematology and Oncology. He sees patients on Main Campus.
Dr. Hanna is board certified in pediatrics and pediatric hematology-Oncology. He earned his medical degree from Aleppo University Faculty of Medicine in Aleppo, Syria. His post-graduate training in USA includes a pediatric residency at Duke University Medical Center in Durham, North Carolina, and a pediatric hematology-oncology fellowship at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital in Seattle, Washington.
Dr. Hanna is a member of several professional organizations, including the American Society of Pediatric Hematology Oncology, American Society of Hematology, and the American Society of Bone Marrow Transplant.
Dr. Hanna has published several research articles in peer-reviewed journals, and has presented at professional association meetings.
His specialty interests include treatment of children with leukemia / Lymphoma and solid tumors that require Hematopoietic Stem Cell Transplantation to consolidate the treatment for their malignant disease, and he also very interested in treatment of inherited non-malignant disorders like primary immunodeficiency like SCID or other inherited metabolic diseases which Hematopoietic Stem Cell Transplantation could offer the potential to restore normal hematological and immunologic function.
He is especially interested in identifying successful conditioning treatments with less side effects especially for non-malignant diseases like hematological diseases (sickle cell disease, thalassemia major, severe aplastic anemia, Fanconi anemia, etc) or primary immune deficiency disorders, such as Severe Combined Immune deficiency, Wiskott-Aldrich Syndrome, and IPEX.
His clinical research is aimed at identifying genetic factors that affect outcomes post bone marrow transplantation from unrelated donor. He is also exploring the role of hematopoietic and mesenchymal stem cells in auto-immune disorders and degenerative disorders.